sera – Page 24 – Communicable Diseases Research

SARS-CoV-2 proteome microarray for COVID-19 patient sera profiling

COVID-19 환자 혈청 프로파일링을 위한 SARS-CoV-2 프로테옴 마이크로어레이

Article

Published on 2022-02-282022-09-12
Journal: STAR protocols [Category] COVID19(2023년), MERS, SARS, 진단,

Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination

CoronaVac 백신 접종 후 Omicron, Gamma 및 Delta SARS-CoV-2 변이체에 대한 중화 항체 생성

Article

Published on 2022-02-252022-09-11
Journal: Revista do Instituto de Medicina Tropical de São [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] antibody Antibody titers booster booster dose Brazil CoronaVac COVID-19 pandemic Cytopathic effect Delta dose elicited evaluated Gamma Generation Health care Health care worker immunization immunized individual Infection limit median Most patients multiple mutation multiple mutations Neutralization antibody neutralization test Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing antibody response neutralizing antibody responses Neutralizing antibody titer neutralizing capacity omicron Omicron variants Patient Pfizer Prevent raised SARS- CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants second vaccination sera serum samples short duration subject subsequent tested undetectable vaccination Vaccine variant variants was performed were measured
[DOI] 10.1590/S1678-9946202264019 PMC 바로가기 [Article Type] Article

Metabolomic analyses reveal new stage-specific features of COVID-19

대사체 분석은 COVID-19의 새로운 단계별 특징을 보여줍니다

Article

Published on 2022-02-242022-09-12
Journal: The European Respiratory Journal [Category] COVID19(2023년), MERS, SARS, 진단,

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections

감염 후 SARS-CoV-2 변종에 대한 교차 중화 폭 및 수명

Article

Published on 2022-02-242022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Antibody titer Antibody titers B.1.1.7 B.1.351 breadth center convalescent sera coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 cross-neutralizing D614G D614G mutation decrease epitope Epitopes infected with SARS-CoV-2 Infection Longevity maintain neutralization Neutralizing activity Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers not significantly different P.1 pandemic Patient patients produced Protective public health recognize respiratory responsible SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants selected sera several variant several variants Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly sustained variant variants variants of concern virus Virus neutralization viruses VoC VOCs was performed
[DOI] 10.3389/fimmu.2022.773652 PMC 바로가기 [Article Type] Article

Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays

2020년 4월부터 2021년 3월까지 캐나다 헌혈자의 SARS-CoV-2 혈청유병률 추정: 다중 분석으로 정확도 개선

Research Article

Published on 2022-02-232022-09-10
Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 진단, 치료법,

[키워드] 95% CI Abbott advent Analysis Antibody Response antibody tests approach Architect assays blood donor Blood donors can be used Chicago IL cross-sectional cross-sectional design cross-sectional study diagnostic diagnostic testing disease Epidemics evaluate evaluated fatality full-length spike glycoprotein gold gold standard house identify IgG IgG antibodies IgG ELISA Improving indicate Infection infections laboratory assay laboratory assays latent class latent class analysis less Multiple nucleocapsid nucleocapsid antigen occur Pandemics Prevalence provide public health random RBD Receptor binding domain recognizing reference standard Reference standards repeated resulting SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody Sensitivity and specificity sera serological data serological studies SEROLOGICAL STUDY Seropositivity Seroprevalence seroreversion silent spike spike glycoprotein Support Surveillance vaccination
[DOI] 10.1128/spectrum.02563-21 PMC 바로가기 [Article Type] Research Article

Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?

Immunology

Published on 2022-02-222022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] activating anti-SARS-CoV-2 antibody antibody approach assessments average Better calibrated Cell characterisation collected comparable complement component convalescent convalescent plasma COVID-19 COVID-19 epidemic COVID-19 patient decrease effort evidenced expressed Immunocompromised lack NAbs neutralisation neutralising antibody passive antibody therapy positive correlation Quality ranged SARS-CoV-2 SARS-CoV-2 specific antibodies SARS-CoV-2–specific antibody sera serological data severity Standard Standardization the disease titre virus WHO wild-type SARS-CoV-2 wild-type virus neutralization assay
[DOI] 10.3389/fimmu.2022.816159 PMC 바로가기 [Article Type] Immunology

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

SARS-CoV-2 감염 전후에 백신 접종은 강력한 체액 반응과 변이체를 효과적으로 중화시키는 항체로 이어집니다.

Article

Published on 2022-02-182022-09-11
Journal: Science Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] age antibody Antibody Response Antibody responses antigen exposure boost breadth Breakthrough infection breakthrough infections coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 current Effect groups humoral humoral immune response immune immune response immune responses Immunity individual Infection morbidity and mortality natural infection neutralize Neutralizing antibody response neutralizing antibody responses no correlation no infection occur pandemic quantity reduce respiratory Respiratory Coronavirus robust SARS-CoV-2 SARS-COV-2 infection sera vaccinated individuals vaccination Vaccine variant
[DOI] 10.1126/sciimmunol.abn8014 PMC 바로가기 [Article Type] Article

Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera

Article

Published on 2022-02-172022-10-28
Journal: Viruses [Category] COVID-19, COVID19(2023년), Fulltext, MERS, SARS,

[키워드] acute respiratory distress analyses Analysis analyzed Antibody binding antigen–antibody complex ARDS binding binding antibody BSL3 cell fusion assays characterized comparable Comparative complex convalescent individuals convalescent sera correlation COVID-19 defined ELISA explained fraction heterogeneity hospitalized COVID-19 patient humoral immune response IgA antibodies immune Interaction investigation less Neutralization assay Neutralizing neutralizing capacity performed plaque reduction neutralization PRNT quantification RBD-ACE2 robust SARS-CoV-2 sera significantly higher stability syncytium formation syndrome the antibodies
[DOI] 10.3390/v14020410 PMC 바로가기 [Article Type] Article

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents

우한 COVID-19 회복기에서 SARS-CoV-2 오미크론 변종에 대한 혈청 중화의 급격한 감소

Coronaviruses

Published on 2022-02-162022-09-10
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종,

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens

Observation

Published on 2022-02-162022-10-30
Journal: Microbiology Spectrum [Category] COVID-19, COVID19(2023년), SARS,

[키워드] adjuvant aluminum animal models Antigen Beta candidate vaccine Combination COVID-19 COVID-19 vaccine defined Delta delta variant distribution driven by Efficacy elevated humoral hydroxide immune response Immunity immunity after vaccination immunogenic in vitro induced mice NAb NAb titer NAbs neutralize Neutralizing Pathways plasma produced PROTECT Protective protective immunity Protein receptor response Safe SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 variant SARS-CoV-2 variants sera spike Spike protein subunit Subunit vaccine Support sustained the SARS-CoV-2 TLR TLR8 trimeric trimeric spike vaccination Vaccine vaccine candidate variant
[DOI] 10.1128/spectrum.01695-21 PMC 바로가기 [Article Type] Observation